Table 2 Injection route, 99mTc activity, labelling efficiency, number and viability of the labelled-ePB-MSCs injected to each dog in the different studies
Study | Dog | Injection route | Injected 99mTc activity (mCi) | Labelling efficiency (%) | Number of MSCs | Viability of MSCs (%) |
|---|---|---|---|---|---|---|
1 | 1 | IV | 17.36 | 71.50 | 415,000 | 87.95 |
2 | 17.64 | 59.58 | 305,000 | 88.52 | ||
3 | 19.40 | 67.80 | 385,000 | 83.00 | ||
4 | 16.38 | 60.15 | 335,000 | 79.10 | ||
2 | 5 | IM | 18.45 | 72.78 | 465,000 | 90.32 |
6 | 19.05 | 73.21 | 775,000 | 95.48 | ||
7 | 24.04 | 77.83 | 695,000 | 93.53 | ||
8 | 15.00 | 53.65 | 775,000 | 95.48 | ||
5 | SC | 15.62 | 66.21 | 825,000 | 96.96 | |
6 | 20.15 | 69.18 | 785,000 | 93.63 | ||
7 | 23.38 | 78.02 | 760,000 | 94.74 | ||
8 | 23.49 | 78.34 | 730,000 | 94.52 | ||
3 | 6 | IV | 19.56 | 80.65 | 1,810,000 | 95.58 |
7 | 27.85 | 83.04 | 1,950,000 | 97.44 | ||
8 | 21.37 | 83.82 | 1,610,000 | 93.17 |